Chemical activators of IIGP can initiate a series of intracellular events leading to the protein's functional activation. Phorbol 12-myristate 13-acetate (PMA) directly activates protein kinase C (PKC), which is known to phosphorylate a wide array of proteins. This PKC-mediated phosphorylation cascade can directly affect IIGP, leading to its activation. Similarly, forskolin, by increasing intracellular cyclic AMP (cAMP) levels, activates protein kinase A (PKA). PKA then has the capability to phosphorylate IIGP, which is a common regulatory mechanism for protein activation. Ionomycin, through its role in increasing intracellular calcium levels, can activate calcium-dependent kinases. These kinases, upon activation, can target IIGP for phosphorylation, thus altering its activity state. The cAMP analogs, Dibutyryl cAMP and 8-Br-cAMP, bypass the cell surface receptors and directly activate PKA, which subsequently can lead to the phosphorylation and activation of IIGP.
In the context of kinase activation, staurosporine, at sub-inhibitory concentrations, can activate a wide range of kinases, some of which are likely to target IIGP. Epigallocatechin gallate (EGCG) can modulate the activity of various kinases and phosphatases, potentially leading to the phosphorylation and activation of IIGP. Thapsigargin disrupts calcium homeostasis, which may result in the activation of kinases that phosphorylate IIGP. Phosphatase inhibitors, such as Calyculin A and Okadaic Acid, can prevent the dephosphorylation of proteins, thus maintaining IIGP in an activated state. Zinc Pyrithione, by altering metal ion dynamics, can indirectly influence the activities of kinases and phosphatases that modulate IIGP activation. Anisomycin, known to activate stress-activated protein kinases, can also lead to the phosphorylation and subsequent activation of IIGP. This multi-faceted approach, involving a variety of chemicals, illustrates the complex regulatory environment that controls the activity state of IIGP.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Activates PKC which can phosphorylate IIGP1, leading to its activation. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Raises cAMP, activating PKA which can subsequently phosphorylate IIGP1. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Increases Ca2+, potentially activating kinases that phosphorylate IIGP1. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
cAMP analog that activates PKA, possibly leading to IIGP1 phosphorylation. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
At low doses, activates kinases that could phosphorylate IIGP1. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
May alter kinase activity, leading to phosphorylation of IIGP1. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Alters calcium homeostasis, which may activate kinases to phosphorylate IIGP1. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A sc-24000C | 10 µg 100 µg 1 mg | $160.00 $750.00 $3000.00 | 59 | |
Inhibits phosphatases, potentially maintaining phosphorylation of IIGP1. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Phosphatase inhibitor which may result in increased phosphorylation of IIGP1. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $47.00 | ||
Modulates metal ions, indirectly affecting kinase activity linked to IIGP1 activation. | ||||||